Medaxonum Lido (Ceftriaxone, Lidocaine Hydrochloride)

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which blocks the cross‑linking of peptidoglycan strands. This disruption weakens the cell wall, leading to bacterial lysis and death, providing broad‑spectrum antibacterial activity.

The dosage of Medaxonum Lido is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. No fixed regimen is provided here; the prescriber sets the appropriate dose.

Ceftriaxone is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but a lack of well‑controlled human data. It may be used during pregnancy only if clearly needed. Lidocaine also has a favorable safety profile, but the overall decision should be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with earlier‑generation cephalosporins, ceftriaxone offers a longer half‑life, allowing once‑daily dosing, and broader coverage against Gram‑negative organisms. The addition of lidocaine distinguishes Medaxonum Lido by providing immediate local anaesthesia, which many other ceftriaxone formulations lack.

Store the product at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use and discard any solution that appears discoloured or contains particles.

Medaxonum Lido is given by intramuscular injection using aseptic technique. The dose is prepared in a sterile syringe, injected into a large muscle (e.g., gluteus or thigh), and the lidocaine component helps reduce injection‑related pain.

Serious adverse reactions include anaphylaxis, severe allergic skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and rare seizures. Patients should be monitored for signs of hypersensitivity, gastrointestinal severe diarrhea, or neurologic changes during therapy.

Patients with a known hypersensitivity to ceftriaxone, other cephalosporins, penicillins, or lidocaine should avoid the product. It is also contraindicated in individuals with a history of severe allergic reactions to beta‑lactam antibiotics or local anesthetics.